Immunovant Inc (IMVT) - Net Assets
Based on the latest financial reports, Immunovant Inc (IMVT) has net assets worth $735.39 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($852.49 Million) and total liabilities ($117.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Immunovant Inc (IMVT) strategic investment index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $735.39 Million |
| % of Total Assets | 86.26% |
| Annual Growth Rate | N/A |
| 5-Year Change | 81.47% |
| 10-Year Change | N/A |
| Growth Volatility | 134012.36 |
Immunovant Inc - Net Assets Trend (2018–2026)
This chart illustrates how Immunovant Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Immunovant Inc.
Annual Net Assets for Immunovant Inc (2018–2026)
The table below shows the annual net assets of Immunovant Inc from 2018 to 2026. Also explore Immunovant Inc equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | $852.59 Million | +20.52% |
| 2025-03-31 | $707.45 Million | +14.52% |
| 2024-03-31 | $617.76 Million | +70.42% |
| 2023-03-31 | $362.49 Million | -22.84% |
| 2022-03-31 | $469.82 Million | +20.01% |
| 2021-03-31 | $391.48 Million | +316.16% |
| 2020-03-31 | $94.07 Million | +383041.90% |
| 2019-03-31 | $24.55K | +101.64% |
| 2018-03-31 | $-1.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Immunovant Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 174512900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $20.00K | 0.00% |
| Other Comprehensive Income | $730.00K | 0.09% |
| Other Components | $2.60 Billion | 304.60% |
| Total Equity | $852.59 Million | 100.00% |
Immunovant Inc Competitors by Market Cap
The table below lists competitors of Immunovant Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NISSAN MOTOR SP. ADR/2
F:NISE
|
$7.52 Billion |
|
Central Bancompany, Inc. Class A Common Stock
NASDAQ:CBC
|
$7.52 Billion |
|
Pegatron Corp
TW:4938
|
$7.52 Billion |
|
ICON Public Limited Company
F:IJF
|
$7.52 Billion |
|
South Bow Corporation
TO:SOBO
|
$7.51 Billion |
|
Nantong Jianghai Capacitor Co Ltd
SHE:002484
|
$7.50 Billion |
|
Stora Enso Oyj R
HE:STERV
|
$7.50 Billion |
|
Dosilicon Co Ltd
SHG:688110
|
$7.50 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immunovant Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 707,447,000 to 852,592,000, a change of 145,145,000 (20.5%).
- Net loss of 505,606,000 reduced equity.
- New share issuances of 544,194,000 increased equity.
- Other comprehensive income decreased equity by 729,000.
- Other factors increased equity by 107,286,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-505.61 Million | -59.3% |
| Share Issuances | $544.19 Million | +63.83% |
| Other Comprehensive Income | $-729.00K | -0.09% |
| Other Changes | $107.29 Million | +12.58% |
| Total Change | $- | 20.52% |
Book Value vs Market Value Analysis
This analysis compares Immunovant Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.78x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-03-31 | $-0.15 | $36.38 | x |
| 2019-03-31 | $0.00 | $36.38 | x |
| 2020-03-31 | $2.18 | $36.38 | x |
| 2021-03-31 | $4.46 | $36.38 | x |
| 2022-03-31 | $4.28 | $36.38 | x |
| 2023-03-31 | $2.95 | $36.38 | x |
| 2024-03-31 | $4.47 | $36.38 | x |
| 2025-03-31 | $4.67 | $36.38 | x |
| 2026-03-31 | $4.67 | $36.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immunovant Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -59.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.12x
- Recent ROE (-59.30%) is below the historical average (-39.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-136.59 Million |
| 2019 | -1.83% | 0.00% | 0.00x | 16.50x | $-2.91K |
| 2020 | -70.57% | 0.00% | 0.00x | 1.16x | $-75.79 Million |
| 2021 | -27.44% | 0.00% | 0.00x | 1.05x | $-146.58 Million |
| 2022 | -33.36% | 0.00% | 0.00x | 1.10x | $-203.71 Million |
| 2023 | -58.20% | 0.00% | 0.00x | 1.12x | $-247.21 Million |
| 2024 | -41.98% | 0.00% | 0.00x | 1.08x | $-321.11 Million |
| 2025 | -58.50% | 0.00% | 0.00x | 1.10x | $-484.58 Million |
| 2026 | -59.30% | 0.00% | 0.00x | 1.12x | $-590.87 Million |
Industry Comparison
This section compares Immunovant Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $201,571,196
- Average return on equity (ROE) among peers: -90.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immunovant Inc (IMVT) | $735.39 Million | 0.00% | 0.16x | $7.51 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $112.13 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $44.03 Million | -144.75% | 1.47x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.36 Billion |
| Arbutus Biopharma Corp (ABUS) | $76.58 Million | -43.75% | 0.24x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $723.96K | -677.23% | 9.41x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $71.77 Million | -22.23% | 0.06x | $8.92 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $732.79 Million | 30.90% | 0.62x | $4.75 Billion |
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinat… Read more